Deucravacitinib

Pregnancy
categoryRoutes of
administrationBy mouthDrug classTyrosine kinase 2 (TYK2) inhibitorATC codeLegal statusLegal status Pharmacokinetic dataBioavailability99%Protein binding82–90%MetabolismLiver (primarily CYP1A2)MetabolitesBMT-153261 (active)Elimination half-life10 hoursExcretionFeces, urineIdentifiersCAS NumberPubChem CIDDrugBankChemSpiderUNIIKEGGChEMBLECHA InfoCard100.329.069 Chemical and physical dataFormulaC₂₀H₁₉D₃N₈O₃Molar mass425.466 g·mol⁻¹3D model (JSmol)

Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis.^[7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.^[7] It was developed by Bristol Myers Squibb.^[10]

Deucravacitinib was approved for medical use in the United States in September 2022,^[7][11][12] and in Australia in December 2022.^[1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[13][14]

Medical uses

Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis.^[7]

Mechanism of action

It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).^[15]

Molecule design

The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium.^[16]

Society and culture

Legal status

In January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis.^[8][17] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.^[8][17] Deucravacitinib was approved for medical use in the European Union in March 2023.^[8]

References